Summary
β-Adrenoceptor blocking drugs have been used for the treatment of acute stress reactions, adjustment disorders, generalised anxiety, panic disorder and agoraphobia. In general they are effective in these disorders if somatic or autonomic symptoms are prominent but not extreme in degree. Thus, they are of more value for the relatively mild tremor of the anxious violinist in public performance than in the severe shaking noticed during a panic attack. It is most likely that β-blockers act primarily by blocking peripheral adrenergic β-receptors; symptoms that are mediated through β-stimulation, such as tremor and palpitations, are helped most. Improvement is noted within 1 to 2 hours and with relatively low doses (e.g. propranolol 40 mg/day). Some recent studies, however, have suggested that when longer treatment using higher doses (e.g. propranolol 160 mg/day) is given, improvement in other forms of anxiety is noted after several weeks of treatment, β-blocking drugs are useful adjuncts to existing treatments for anxiety and are likely to enjoy wider use now that benzodiazepines are being avoided due to their dependence risks.
Similar content being viewed by others
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), 3rd ed., American Psychiatric Association, Washington, 1987
Bonn JA, Turner P. D-Propranolol and anxiety. Lancet 1: 1355–1356, 1971
Bonn JA, Turner P, Hicks DC. Beta-adrenergic-receptor blockade with practolol in treatment of anxiety. Lancet 1: 814–815, 1972
Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. American Journal of Medicine 72: 88–94, 1982
Brewer C. Beneficial effect of beta-adrenergic blocking agents on ‘exam nerves’. Lancet 2: 435, 1972
Burrows GD, Davies B, Fail L, Poynton S, Stevenson H. A placebo controlled trial of diazepam and oxprenolol for anxiety. Psychopharmacology 50: 177–179, 1976
Cleghorn JM, Peterfry G, Pinter EJ, Pattee CJ. Verbal anxiety and the beta-adrenergic receptors: a facilitating mechanism? Journal of Nervous and Mental Disease 151: 266–272, 1970
Eliasch H, Lager CG, Norrback K, Rosen A, Scott H. The beta-adrenergic receptor blockade modification of the systemic haemodynamic effects of link trainer simulated flight. Forsvarmedicin 3 (Suppl. 2): 120–129, 1967
Falloon IR, Lloyd GG, Harpin R. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. Journal of Nervous and Mental Disease 169: 180–184, 1981
Frohlich ED, Dunstan HP, Page IH. Hyperdynamic beta-adrenergic circulatory state. Archives of Internal Medicine 117: 614–619, 1966
Gorman JM, Gorman LK. Drug treatment of social phobias. Journal of Affective Disorders 13: 183–192, 1987
Gorman JM, Liebowitz MR, Fyer AJ, Campeas R, Klein DF. Treatment of social phobia with atenolol. Journal of Clinical Psychopharmacology 5: 298–301, 1985
Gottschalk LA, Stone WN, Gleser GC. Peripheral versus central mechanisms accounting for anti-anxiety effect of propranolol. Psychosomatic Medicine 36: 47–56, 1974
Granville-Grossman KL, Turner P. The effect of propranolol on anxiety. Lancet 1: 788–790, 1966
Hafner J, Milton F. The influence of propranolol on the exposure in vivo of agoraphobics. Psychological Medicine 7: 417–425, 1977
Hallstrom C, Treasaden I, Edwards JG, Lader M. Diazepam, propranolol and their combination in the management of chronic anxiety. British Journal of Psychiatry 139: 417–421, 1981
Hartley LR, Ungapen S, Davie I, Spencer DJ. The effect of beta adrenergic blocking drugs on speakers’ performance and memory. British Journal of Psychiatry 142: 512–517, 1983
Holmberg G, Levi L, Mathe A, Rosen A, Scott H. Plasma cate-cholamines and the effects of adrenergic beta-receptor blockade on cardiovascular reactions and subjective feelings during emotional stress. Forsvarmedicin 3 (Suppl. 2): 201–221, 1967
Hunninghake DB, Azarnoff DL, Waxman D. Drug inhibition of catecholamine-induced metabolic effects in humans. Annäls of the New York Academy of Sciences 139: 971–981, 1967
James IM. Practical aspects of the use of beta-blockers in anxiety states: situational anxiety. Postgraduate Medical Journal 60 (Suppl. 2): 19–25, 1984
James IM, Burgoyne W, Savage IT. Effect of pindolol on stress-related disturbances of musical performances: preliminary communication. Journal of the Royal Society of Medicine 76: 194–196, 1983
James IM, Griffiths DNW, Pierson RM, Newbury P. Effect of oxprenolol on stage-fright in musicians. Lancet 2: 952–954, 1977
James IM, Temple-Savage I. Beneficial effects of nadolol on anxiety induced disturbance of performance in musicians: a comparison with diazepam and placebo. American Heart Journal 108: 1150–1155, 1984
Jefferson D, Jenner P, Marsden CD. Beta-adrenoceptor antagonists in essential tremor. Journal of Neurology, Neurosurgery and Psychiatry 42: 904–909, 1979
Johnson G, Singh B, Leeman M. Controlled evaluation of the beta-adrenoreceptor blocking drug oxprenolol in anxiety. Medical Journal of Australia 1: 909–912, 1976
Kabes J, Dostal T. Clinical effects of beta-adrenergic blockers in psychiatry (propranolol, trimepranol). Activitas Nervosa Superior 17: 279–280, 1975
Kathol RG, Noyes R, Slymen DJ, Crowe RB, Clancy J, et al. Propranolol in chronic anxiety disorders: a controlled study. Archives of General Psychiatry 37: 1361–1365, 1980
Kellner R, Collins AC, Shulman RS, Pathak D. Short-term anti-anxiety effects of propranolol HC1. Journal of Clinical Pharmacology 14: 301–304, 1974
Kolb LC, Bums BC, Griffiths S. Propranolol and clonidine in the treatment of post-traumatic stress disorders of war. In van der Kolk BA (Ed.) Post-traumatic stress disorder psychological and biological sequelae, American Psychiatric Press, Washington, 1984
Krishnan G. Oxprenolol in the treatment of examination nerves. Scottish Medical Journal 20: 288–289, 1975
Liden S, Gottfriess CG. Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians. Lancet 2: 529, 1974
MacDonald AG, Ingram CG, McNeill RS. The effect of propranolol on airway resistance. British Journal of Anaesthesia 39: 919–926, 1967
Marks I. Agoraphobia, panic disorder and related conditions in the DSM-III-B and ICD-10. Journal of Psychopharmacology 1:6–12, 1987
Marsden CW. Propranolol in neurocirculatory asthenia and anxiety. Postgraduate Medical Journal (Suppl. 47): 100–103,1971
Marsden CD, Foley TH, Owen DAL, McAllister RG. Peripheral beta-adrenergic receptors concerned with tremor. Clinical Science 33: 53–56, 1967
McMillin WP. Oxprenolol in the treatment of anxiety due to environmental stress. American Journal of Psychiatry 132: 965–968, 1975
Munjack DJ, Rebal R, Shaner R, Staples F, Braun R, et al. Imipramine versus propranolol for the treatment of panic attacks: a pilot study. Comprehensive Psychiatry 26: 80–89, 1985
Neftel KA, Adler RH, Kappell L, Rossi M, Dolder M, et al. Stage fright in musicians: a model illustrating the effect of beta-blockers. Psychosomatic Medicine 44: 461 -469, 1982
Nordenfelt I, Persson S, Redfors A. Effect of a new adrenergic beta-blocking agent, H 56-28, on nervous heat complaints. Acta Medica Scandinavica 184: 465–471, 1968
Noyes R, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, et al. Diazepam and propranolol in panic disorder and agoraphobia. Archives of General Psychiatry 41: 287–292, 1984
Noyes R, Kathol R, Clancy J, Crowe RR. Antianxiety effects of propranolol: a review of clinical studies. In Klein DF & Rabkin J (Eds) Anxiety: new research and changing concepts, pp. 81–93, Raven Press, New York, 1981
Owen RT, Tyrer P. Benzodiazepine dependence — a review of the evidence. Drugs 25: 385–398, 1983
Pitts FN, Allen RE. Beta-adrenergic blockade in the treatment of anxiety. In Mathew RJ (Ed.) Biology of anxiety, pp. 134–161, Brunner/Mazel, New York, 1982
Quality Assurance Project. Treatment outlines for the management of anxiety states. Australian and New Zealand Journal of Psychiatry 19: 138–151, 1985
Ramsey I, Greer S, Bagley C. Propranolol in neurotic and thyrotoxic anxiety. British Journal of Psychiatry 122: 555–560, 1973
Rickels K, Case GW, Winokur A, Swenson C. Long-term benzodiazepine therapy: benefits and risks. Psychopharmacology Bulletin 20: 608–615, 1984
Seivewright N. Relationship between life events and personality in psychiatric disorder. Stress Medicine 3: 163–168, 1987
Shehi M, Patterson WM. Treatment of panic attacks with alprazolam and propranolol. American Journal of Psychiatry 141: 900–901, 1984
Silverstone JT. Some new approaches to the treatment of anxiety. Psychopharmacology Bulletin 10: 10–11, 1974
Suzman MM. The use of beta-adrenergic blockade with propranolol in anxiety states. Postgraduate Medical Journal (Suppl. 47): 104–108, 1971
Tanna VT, Pennigroth RP, Woolson RF. Propranolol in the treatment of anxiety neurosis. Comprehensive Psychiatry 18: 319–325, 1977
Thyer BA, Hinle J, Curtus GC, Cameron OG, Nesse RM. The comparison of panic disorder and agoraphobia with panic attacks. Comprehensive Psychiatry 26: 208–214, 1985
Tyrer P. The role of bodily feelings in anxiety. Oxford University Press, London, 1976
Tyrer PJ. The use of beta-blocking drugs in psychiatry and neurology. Drugs 20: 300–308, 1980
Tyrer P. The concept of somatic anxiety. British Journal of Psychiatry 140: 325, 1982
Tyrer P. Classification of anxiety disorders: a critique of DSM-III. Journal of Affective Disorders 11: 99–104, 1986
Tyrer P. Dependence as a limiting factor in the clinical use of minor tranquillisers. Pharmacology and Therapeutics 36: 173–188, 1988
Tyrer P, Casey P, Ferguson B. Personality disorder and mental illness. In Tyrer P (Ed.) Personality disorder: diagnosis, management and course, pp. 93–104, Wright, London, 1988
Tyrer PJ, Lader MH. Effects of beta-adrenergic blockade with sotalol in chronic anxiety. Clinical Pharmacology and Therapeutics 14: 418–426, 1973
Tyrer PJ, Lader MH. Response to propranolol and diazepam in somatic and psychic anxiety. British Medical Journal 2: 14–16, 1974a
Tyrer PJ, Lader MH. Physiological responses to propranolol and diazepam in chronic anxiety. British Journal of Clinical Pharmacology 1: 387–390, 1974b
Tyrer P, Owen R, Dawling S. Gradual withdrawal of diazepam after long-term therapy. Lancet 1: 1402–1406, 1983
Tyrer P, Rutherford D, Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1: 520–522, 1981
Wheatley D. Comparative effects of propranolol and chlordiazepoxide in anxiety states. British Journal of Psychiatry 115: 1411–1412, 1969
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tyrer, P. Current Status of β-Blocking Drugs in the Treatment of Anxiety Disorders. Drugs 36, 773–783 (1988). https://doi.org/10.2165/00003495-198836060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198836060-00006